Filing Flows › Comparisons › NWBO vs MREO
Northwest Biotherapeutics vs Mereo BioPharma Group: NWBO and MREO compared
Northwest Biotherapeutics is the larger company: $807K of revenue in its latest quarter (Q2 2026) against $800K for Mereo BioPharma Group (Q3 2026).
Where the money goes: NWBO and MREO
Northwest Biotherapeutics (NWBO) · Q2 2026
Northwest Biotherapeutics, Q2 2026: revenue $807K (+516% year over year), net loss $15.4M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Mereo BioPharma Group (MREO) · Q3 2026
Mereo BioPharma Group, Q3 2026: revenue $800K, operating margin -777.2%, net loss $5.9M, operating cash flow −$4.1M. The chart follows the revenue to costs, profit and cash.
| Northwest Biotherapeutics (NWBO) | Mereo BioPharma Group (MREO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $807K | $800K |
| Revenue growth, Y/Y | +516% | — |
| Operating margin | n/m | -777.2% |
| Net earnings | −$15.4M | −$5.9M |
| Net margin | — | -732.9% |
| Operating cash flow | −$7.2M | −$4.1M |
Questions
Which is bigger, Northwest Biotherapeutics or Mereo BioPharma Group?
Northwest Biotherapeutics is the larger company: $807K of revenue in its latest quarter (Q2 2026) against $800K for Mereo BioPharma Group (Q3 2026).
More: Northwest Biotherapeutics earnings · how Northwest Biotherapeutics makes money · Mereo BioPharma Group earnings · how Mereo BioPharma Group makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.